Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.45 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.44 |
| ▸ | LTA4H | P09960 | 3/20 | 0.41 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7427755 | 1.00 | CHRNB2 (0.45) | CHRNB2CHRNA4CHRNB4CHRNA3LTA4H | |
| SCHEMBL12083445 | 1.00 | CHRNB2 (0.45) | CHRNB2CHRNA4CHRNB4CHRNA3LTA4H | |
| SCHEMBL7425051 | 0.94 | LTA4H (0.43) | CHRNB2CHRNA4LTA4HALDH1A1 | |
| SCHEMBL7420348 | 0.94 | LTA4H (0.43) | CHRNB2CHRNA4LTA4HALDH1A1 | |
| SCHEMBL7420352 | 0.94 | LTA4H (0.43) | CHRNB2CHRNA4LTA4HALDH1A1 | |
| SCHEMBL21743272 | 0.84 | CHRNB2 (0.43) | CHRNB2CHRNA4CHRNB4CHRNA3LTA4H | |
| SCHEMBL18568746 | 0.81 | CHRNB2 (0.41) | CHRNB2CHRNA4CHRNB4CHRNA3LTA4H | |
| SCHEMBL12403589 | 0.80 | CHRNB2 (0.36) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA5 | |
| SCHEMBL3332629 | 0.79 | LTA4H (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3LTA4H | |
| SCHEMBL19557797 | 0.78 | CHRNB2 (0.39) | CHRNB2CHRNA4CHRNB4CHRNA3LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. | 2023-11-16 | — | — | US | disclosed |
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | Epizyme, Inc. (US) | 2023-06-13 | — | — | US | disclosed |
| EP-4105203-A1 | SPIRO-CONDENSED INDOLE COMPOUNDS AS EHMT2 INHIBITORS | Epizyme Inc (US) | 2022-12-21 | — | — | EP | disclosed |
| US-11236068-B2 | Fused ring compounds | GENENTECH, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210230142-A9 | FUSED RING COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-07-29 | — | — | US | disclosed |
| US-20210213014-A1 | METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES | Epizyme, Inc. | 2021-07-15 | — | — | US | disclosed |
| CN-107667097-B | Separation of enantiomers of 3-ethylbicyclo [3.2.0] hept-3-en-6-one | 诺瓦色生物公司 | 2021-02-12 | — | — | CN | disclosed |
| US-20200317642-A1 | AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND DERIVATIVES THEREOF | Epizyme, Inc. | 2020-10-08 | — | — | US | disclosed |
| US-20200181118-A1 | FUSED RING COMPOUNDS | GENENTECH INC (US) | 2020-06-11 | — | — | US | disclosed |
| US-20200113901-A1 | METHODS OF USING EHMT2 INHIBITORS | Epizyme, Inc. | 2020-04-16 | — | — | US | disclosed |
| US-9035103-B2 | Optical resolution methods for bicyclic compounds using asymmetric catalysts | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-05-19 | — | — | US | disclosed |
| US-20150087630-A1 | METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER | GENENTECH, INC. (US) | 2015-03-26 | — | — | US | disclosed |
| EP-2792664-A1 | OPTICAL RESOLUTION METHOD FOR BICYCLIC COMPOUND USING ASYMMETRIC CATALYST | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-10-22 | — | — | EP | disclosed |
| US-20140296569-A1 | Optical Resolution Method for Bicyclic Compound Using Asymmetric Catalyst | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-10-02 | — | — | US | disclosed |
| US-20140171407-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20110183938-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2011-07-28 | — | — | US | disclosed |
| US-20110183938-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2011-07-28 | — | — | US | disclosed |
| US-7943639-B2 | Such as 6-benzenesulfonyl-4-piperazin-1-yl-quinoline hydrochloride; for treatment of central nervous system and/or 5- HT6 receptor related disorders; for weight gain/loss | PROXIMAGEN LIMITED (GB) | 2011-05-17 | — | — | US | disclosed |
| EP-0815103-A1 | TRYPSIN AND THROMBIN INHIBITORS | Novartis AG (CH) | 1998-01-07 | — | — | EP | disclosed |
| WO-1996029327-A1 | TRYPSIN AND THROMBIN INHIBITORS | NOVARTIS AG (CH) | 1996-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230142-A9 | FUSED RING COMPOUNDS | KRAS, NRAS, HRAS | CHRNB2 3939/4885CHRNA4 4710/4885CHRNB4 4283/4885 |
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | EHMT2, BHMT, SHMT2 | CHRNB2 2833/4885CHRNA4 4286/4885CHRNB4 3911/4885 |
| US-20140296569-A1 | Optical Resolution Method for Bicyclic Compound Using Asymmetric Catalyst | OXER1, OCIAD2, AOC2 | CHRNB2 2940/4885CHRNA4 2460/4885CHRNB4 2928/4885 |
| US-20200317642-A1 | AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND DERIVATIVES THEREOF | HNMT, EHMT2, SHMT2 | CHRNB2 1153/4885CHRNA4 2709/4885CHRNB4 2582/4885 |
| US-20110183938-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | CHEK1, CHEK2, BUB1B | CHRNB2 3164/4885CHRNA4 3868/4885CHRNB4 3360/4885 |
| US-20150087630-A1 | METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER | IDH3B, IDH3A, EGLN3 | CHRNB2 1905/4885CHRNA4 2044/4885CHRNB4 1873/4885 |
| US-20140171407-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | CHEK1, CHEK2, BUB1B | CHRNB2 3164/4885CHRNA4 3868/4885CHRNB4 3360/4885 |
| US-20200113901-A1 | METHODS OF USING EHMT2 INHIBITORS | EHMT2, EHMT1, BHMT | CHRNB2 546/4885CHRNA4 1620/4885CHRNB4 1105/4885 |
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | EHMT2, BHMT, SHMT2 | CHRNB2 2833/4885CHRNA4 4286/4885CHRNB4 3911/4885 |
| US-20200181118-A1 | FUSED RING COMPOUNDS | KRAS, NRAS, HRAS | CHRNB2 3939/4885CHRNA4 4710/4885CHRNB4 4283/4885 |
| US-11236068-B2 | Fused ring compounds | KRAS, NRAS, HRAS | CHRNB2 3939/4885CHRNA4 4710/4885CHRNB4 4283/4885 |
| US-20210213014-A1 | METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES | EHMT2, BHMT2, BHMT | CHRNB2 1911/4885CHRNA4 3776/4885CHRNB4 3492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.